Sample Size and Data Monitoring for Clinical Trials With Extremely Low Incidence Rates

被引:0
|
作者
Shein-Chung Chow
Shih-Ting Chiu
机构
[1] Duke University School of Medicine,Department of Biostatistics and Bioinformatics
[2] National Taiwan University,Division of Biometry, Department of Agronomy
关键词
low incidence rates; precision analysis; maximum error margin; data safety monitoring; Bayesian approach;
D O I
暂无
中图分类号
学科分类号
摘要
In clinical trials, statistical analyses on incidence rates detect significant differences between the responses from groups. Sample size estimation is always one of the key aspects in clinical trials that have limited budgets. A prestudy power analysis for sample size calculation is often performed to select an appropriate sample size that will achieve a desired power (ie, the probability of correctly detecting the significant difference if such a difference truly exists) at a prespecified level of significance. In practice, it is expected that a greater sample size is needed to detect a smaller difference. A much larger sample size is required to detect a relatively small difference, especially for those clinical studies with extremely low incidence rates. Thus, sample size calculation based on prestudy power analysis may not be feasible in practice. In this case, as an alternative, the authors propose to justify a selected sample size based on a precision analysis and a sensitivity analysis. A recommended step-by-step procedure for sample size determination in clinical trials with extremely low incidence rate is given. A statistical procedure for data safety monitoring based on the probability statement during the conduct of the clinical trial is also proposed.
引用
收藏
页码:438 / 446
页数:8
相关论文
共 50 条
  • [21] The proper sample size in clinical orthopedic trials
    Brocai, DRC
    Lukoschek, M
    Hartmann, M
    Loew, M
    [J]. ORTHOPADE, 1998, 27 (05): : 301 - 304
  • [22] An introduction to sample size calculations in clinical trials
    Accordini, Simone
    [J]. EPIDEMIOLOGIA E PSICHIATRIA SOCIALE-AN INTERNATIONAL JOURNAL FOR EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2007, 16 (04): : 299 - 301
  • [23] On cost effectiveness and sample size in clinical trials
    Dijkgraaf, MGW
    [J]. PHARMACOECONOMICS, 2004, 22 (10) : 685 - 688
  • [24] Monitoring the rates of composite events with censored data in phase II clinical trials
    Cheung, YK
    Thall, PF
    [J]. BIOMETRICS, 2002, 58 (01) : 89 - 97
  • [25] Sample size and power for clinical trials that may change sample size during the trial
    Lakatos, E
    Wu, J
    [J]. RECENT ADVANCES IN EXPERIMENTAL DESIGNS AND RELATED TOPICS, 2001, : 95 - 117
  • [26] A practical comparison of blinded methods for sample size reviews in survival data clinical trials
    Todd, Susan
    Valdes-Marquez, Elsa
    West, Jodie
    [J]. PHARMACEUTICAL STATISTICS, 2012, 11 (02) : 141 - 148
  • [27] Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data
    Harden, Markus
    Friede, Tim
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (05) : 1284 - 1299
  • [28] Sample size re-estimation for survival data in clinical trials with an adaptive design
    Togo, Kanae
    Iwasaki, Manabu
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (04) : 325 - 331
  • [29] Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis
    Friede, Tim
    Kieser, Meinhard
    [J]. PHARMACEUTICAL STATISTICS, 2011, 10 (01) : 8 - 13
  • [30] Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation
    Yu, Jun
    Lai, Dejian
    [J]. CONTEMPORARY CLINICAL TRIALS, 2019, 87